Diabetes Care, Vol 21, Issue 1 42-48, Copyright © 1998 by American Diabetes Association

ARTICLES

The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes

CJ Currie, CL Morgan and JR Peters
Department of Public Health Medicine, Bro Taf Health Authority, U.K. currie@cf.ac.uk

OBJECTIVE: To describe the epidemiology and costs of the acute care of peripheral vascular disease, infection, neuropathy, and ulceration in a U.K. population with special consideration of those patients with diabetes. RESEARCH DESIGN AND METHODS: Routine data describing inpatient care for a 4-year period were analyzed (financial years 1991/1992 to 1994/1995). These data had undergone record-linkage to draw together records from the same patients, and records of patients with diabetes were flagged. Cost estimates were determined by attributing a diagnosis-related group cost-weight to each record. RESULTS: A total of 4,245 admissions (1.2% of all admissions) had a primary diagnosis of peripheral vascular disease, infection, neuropathy, or ulceration, and 7,379 (2.1%) admissions had these categories recorded in any one of six diagnostic fields. These figures were generated by 3,159 and 4,751 patients, respectively. This represented a range of crude annual incidence of admission of between 1.9 and 2.9 per 1,000 people. Patients with diabetes accounted for 625 (15.4%) of primary admissions, a crude annual incidence of admission of 18.8 per 1,000. The age-standardized relative risk of admission for patients with diabetes to the nondiabetic population was 7.61 for men and 6.85 for women. The length of stay for patients with diabetes was almost twice that of the nondiabetic population (15.5 vs. 8.7 days). The relative risk of hospital mortality (diabetes vs. non-diabetes) was 2.83. Surgical procedures were carried out on 857 patients, 272 (31.2%) with diabetes. This represented an age-standardized relative risk of 31.19. The estimated cost of admissions for primary diagnoses in these categories over 4 years was 6,128,211 pounds ($9,743,855). Patients with diabetes accounted for 1,236,623 pounds ($1,966,230), an excess of 87% attributable to the diabetic state. CONCLUSIONS: Diabetes is confirmed as a significant risk factor for peripheral vascular disease, infection, neuropathy, and ulceration. The severity of these disorders in terms of increased risk of hospital mortality, length of stay, and risk of surgical procedure is also demonstrated for those patients with diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. T Hirsch, L. Hartman, R. J Town, and B. A Virnig National health care costs of peripheral arterial disease in the Medicare population Vascular Medicine, August 1, 2008; 13(3): 209 - 215. [Abstract] [PDF]

				C.-H. Tseng, C.-K. Chong, C.-P. Tseng, and T.-Y. Tai The association between urinary albumin excretion and ankle-brachial index in elderly Taiwanese patients with type 2 diabetes mellitus Age Ageing, January 1, 2008; 37(1): 77 - 82. [Abstract] [Full Text] [PDF]

				M. Bharara, J. E. Cobb, and D. J. Claremont Thermography and thermometry in the assessment of diabetic neuropathic foot: a case for furthering the role of thermal techniques. International Journal of Lower Extremity Wounds, December 1, 2006; 5(4): 250 - 260. [Abstract] [PDF]

				A. W. Stitt, C. McGoldrick, A. Rice-McCaldin, D. R. McCance, J. V. Glenn, D. K. Hsu, F.-T. Liu, S. R. Thorpe, and T. A. Gardiner Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3 Diabetes, March 1, 2005; 54(3): 785 - 794. [Abstract] [Full Text] [PDF]

				J. F. Reed III An Audit of Lower Extremity Complications in Octogenarian Patients with Diabetes Mellitus International Journal of Lower Extremity Wounds, September 1, 2004; 3(3): 161 - 164. [Abstract] [PDF]

				A. P. Guignard, J. Oberholzer, P.-Y. Benhamou, S. Touzet, P. Bucher, A. Penfornis, F. Bayle, L. Kessler, C. Thivolet, L. Badet, et al. Cost Analysis of Human Islet Transplantation for the Treatment of Type 1 Diabetes in the Swiss-French Consortium GRAGIL Diabetes Care, April 1, 2004; 27(4): 895 - 900. [Abstract] [Full Text] [PDF]

				C. Emanueli, G. Graiani, M. B. Salis, S. Gadau, E. Desortes, and P. Madeddu Prophylactic Gene Therapy With Human Tissue Kallikrein Ameliorates Limb Ischemia Recovery in Type 1 Diabetic Mice Diabetes, April 1, 2004; 53(4): 1096 - 1103. [Abstract] [Full Text] [PDF]

				C. F. Corbett A Randomized Pilot Study of improving Foot Care in Home Health Patients With Diabetes The Diabetes Educator, March 1, 2003; 29(2): 273 - 282. [Abstract] [PDF]

				C. Emanueli, M. B. Salis, A. Pinna, T. Stacca, A. F. Milia, A. Spano, J. Chao, L. Chao, L. Sciola, and P. Madeddu Prevention of Diabetes-Induced Microangiopathy by Human Tissue Kallikrein Gene Transfer Circulation, August 20, 2002; 106(8): 993 - 999. [Abstract] [Full Text] [PDF]

				A. I. Adler, R. J. Stevens, A. Neil, I. M. Stratton, A. J. M. Boulton, and R. R. Holman UKPDS 59: Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes Diabetes Care, May 1, 2002; 25(5): 894 - 899. [Abstract] [Full Text] [PDF]

				K G Harding, H L Morris, and G K Patel Science, medicine, and the future: Healing chronic wounds BMJ, January 19, 2002; 324(7330): 160 - 163. [Full Text] [PDF]

				C. M Nass, J. K Allen, R. M Jermyn, and L. A Fleisher Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease Vascular Medicine, February 1, 2001; 6(1): 35 - 41. [Abstract] [PDF]

				A. Rivard, M. Silver, D. Chen, M. Kearney, M. Magner, B. Annex, K. Peters, and J. M. Isner Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGF Am. J. Pathol., February 1, 1999; 154(2): 355 - 363. [Abstract] [Full Text] [PDF]